In osteosarcoma survival rates could not be improved over the last 30 years. Novel biomarkers are warranted to allow risk stratification of patients for more individual treatment following initial diagnosis. Although previous studies of the tumor microenvironment have identified promising candidates, novel biomarkers have not been translated into routine histopathology. Substantial difficulties regarding immunohistochemical detection and quantification of antigens in decalcified and heterogeneous osteosarcoma might largely explain this translational short-coming. Furthermore, we hypothesized that conventional hot spot analysis is often not representative for the whole section when applied to heterogeneous tissues like osteosarcoma. We aimed...
Osteosarcoma (OST) is the most common type of high-grade primary bone tumor, which mainly affects yo...
Accumulating evidence has supported that osteosarcoma is heterogeneous, and several subtypes have be...
International audienceOsteosarcoma, the most common malignant primary bone tumor, is currently treat...
In osteosarcoma survival rates could not be improved over the last 30 years. Novel biomarkers are wa...
BACKGROUND: In osteosarcoma survival rates could not be improved over the last 30 years. Novel bioma...
<p>(A) Formalin-fixed and paraffin-embedded osteosarcoma sample after CD31 staining with standard he...
<p>(A) Correlation between hot spot and whole slide analyses of CD31-immunoreactive area (in %) of 2...
<p>Systematic evaluation of more than 200 different antigen retrieval conditions, different blocking...
Abstract Background Even though immunotherapy has been an effective treatment for solid tumors, its ...
Ovarian cancer is the most lethal of gynecological cancers with 5-year survival rate of ca. 45%. The...
BACKGROUND: Osteosarcoma is considered a highly vascularized bone tumor with early metastatic dissem...
Osteosarcoma, the most common malignant primary bone tumor, is currently treated with chemotherapy a...
The influence of tumor surrounding microenvironment is often neglected when immunohistochemistry is ...
Introduction Comprehensive analyses using clinical sequences subcategorized osteosarcoma (OS) into s...
Background: VS38c is a monoclonal antibody that recognises a rough endoplasmic reticulum (rER) intra...
Osteosarcoma (OST) is the most common type of high-grade primary bone tumor, which mainly affects yo...
Accumulating evidence has supported that osteosarcoma is heterogeneous, and several subtypes have be...
International audienceOsteosarcoma, the most common malignant primary bone tumor, is currently treat...
In osteosarcoma survival rates could not be improved over the last 30 years. Novel biomarkers are wa...
BACKGROUND: In osteosarcoma survival rates could not be improved over the last 30 years. Novel bioma...
<p>(A) Formalin-fixed and paraffin-embedded osteosarcoma sample after CD31 staining with standard he...
<p>(A) Correlation between hot spot and whole slide analyses of CD31-immunoreactive area (in %) of 2...
<p>Systematic evaluation of more than 200 different antigen retrieval conditions, different blocking...
Abstract Background Even though immunotherapy has been an effective treatment for solid tumors, its ...
Ovarian cancer is the most lethal of gynecological cancers with 5-year survival rate of ca. 45%. The...
BACKGROUND: Osteosarcoma is considered a highly vascularized bone tumor with early metastatic dissem...
Osteosarcoma, the most common malignant primary bone tumor, is currently treated with chemotherapy a...
The influence of tumor surrounding microenvironment is often neglected when immunohistochemistry is ...
Introduction Comprehensive analyses using clinical sequences subcategorized osteosarcoma (OS) into s...
Background: VS38c is a monoclonal antibody that recognises a rough endoplasmic reticulum (rER) intra...
Osteosarcoma (OST) is the most common type of high-grade primary bone tumor, which mainly affects yo...
Accumulating evidence has supported that osteosarcoma is heterogeneous, and several subtypes have be...
International audienceOsteosarcoma, the most common malignant primary bone tumor, is currently treat...